ALXN2220 Placebo Product, Recombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)
ALXN2220-ATTRCM-301
Phase 3 small_molecule active
Quick answer
ALXN2220 Placebo Product, Recombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb) for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM). is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alexion Europe SAS
- Indication
- Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active